selenium (OTC)

Brand and Other Names:Selepen
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 50mcg
  • 100mcg
  • 125mcg
  • 200mcg

tablet extended release

  • 200mcg

capsule

  • 200mcg

injectable solution

  • 40mcg/mL

RDA

Male or female: 55 mcg/day

Pregnancy: 60 mcg/day

Lactating: 70 mcg/day

Supplementation

100-200 mcg/day PO with meals (preferably); may take 50 mcg PO qDay or q6hr

Dosage Forms & Strengths

tablet

  • 50mcg
  • 100mcg
  • 125mcg
  • 200mcg

tablet extended release

  • 200mcg

capsule

  • 200mcg

injectable solution

  • 40mcg/mL

RDA

<6 months: 15 mcg/day

6-12 months: 20 mcg/day

1-3 years: 20 mcg/day

4-8 years: 30 mcg/day

8-13 years: 40 mcg/day

13-18 years: 55 mcg/day

Next:

Interactions

Interaction Checker

and selenium

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (2)

              • baloxavir marboxil

                selenium will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.

              • eltrombopag

                selenium decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours.

              Monitor Closely (13)

              • alendronate

                selenium will decrease the level or effect of alendronate by cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or 30 min after alendronate.

              • bictegravir

                selenium will decrease the level or effect of bictegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer bictegravir on an empty stomach at least 2 h before or 6 h after polyvalent cation containing drugs.

              • deferiprone

                selenium will decrease the level or effect of deferiprone by cation binding in GI tract. Modify Therapy/Monitor Closely. Separate deferiprone administration from ingestion of polyvalent cations by at least 4 h.

              • dolutegravir

                selenium will decrease the level or effect of dolutegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer dolutegravir at least 2 h before or 6 h after polyvalent cations. Administer the dolutegravir/rilpivirine combination at least 4 h before or 6 h after polyvalent cations.

              • eltrombopag

                selenium will decrease the level or effect of eltrombopag by cation binding in GI tract. Modify Therapy/Monitor Closely. Separate eltrombopag administration from polyvalent cations by at least 2 h.

              • etidronate

                selenium will decrease the level or effect of etidronate by cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or after etidronate.

              • ibandronate

                selenium will decrease the level or effect of ibandronate by cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or 1 h after ibandronate.

              • omadacycline

                selenium will decrease the level or effect of omadacycline by cation binding in GI tract. Modify Therapy/Monitor Closely. Do not take polyvalent cations within 4 hr before or after omadacycline.

              • penicillamine

                selenium will decrease the level or effect of penicillamine by cation binding in GI tract. Modify Therapy/Monitor Closely. Separate penicillamine administration from ingestion of polyvalent cations by at least 1 h.

              • raltegravir

                selenium will decrease the level or effect of raltegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer raltegravir at least 2 h before or 6 h after polyvalent cations. Note: Dose separation may not adequately avoid this interaction.

              • risedronate

                selenium will decrease the level or effect of risedronate by cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or 30 min after risedronate.

              • tiludronate

                selenium will decrease the level or effect of tiludronate by cation binding in GI tract. Modify Therapy/Monitor Closely. Avoid administering polyvalent cations 2 hr before or after tiludronate.

              • trientine

                selenium will decrease the level or effect of trientine by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer trientine at least 1 hr before or after polyvalent cations (2 hr if oral iron administered).

              Minor (0)

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Irritability

                Previous
                Next:

                Warnings

                Contraindications

                Undiluted injection into peripheral vein

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: C

                Lactation: Excreted in breast milk; use caution

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Antioxidant; cofactor in glutathione peroxidase; protects cell components from oxidative damage

                Present in selenoproteins as selenocysteine amino acid residue

                Pharmacokinetics

                Excretion: Urine, feces, lungs, skin

                Previous
                Next:

                Images

                BRAND FORM. UNIT PRICE PILL IMAGE
                selenium intravenous
                -
                40 mcg/mL vial
                Selenious Acid intravenous
                -
                60 mcg/mL vial
                Selenious Acid intravenous
                -
                60 mcg/mL vial
                selenium oral
                -
                200 mcg capsule
                selenium oral
                -
                200 mcg tablet

                Copyright © 2010 First DataBank, Inc.

                Previous
                Next:

                Patient Handout

                Select a drug:
                Patient Education
                selenium intravenous

                NO MONOGRAPH AVAILABLE AT THIS TIME

                USES: Consult your pharmacist.

                HOW TO USE: Consult your pharmacist.

                SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

                PRECAUTIONS: Consult your pharmacist.

                DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

                OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

                NOTES: No monograph available at this time.

                MISSED DOSE: Consult your pharmacist.

                STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

                Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

                IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.